Increasing trends of pharmaceutical payments to breast cancer specialists in Japan: A retrospective study from 2016 to 2019
From 2016 to 2019, pharmaceutical payments to Japanese breast cancer specialists increased significantly, coinciding with new drug introductions. The concentration of payments among a select group of specialists raises concerns about potential influences on clinical decision-making and guideline recommendations.
Authors
- Akihiko Ozaki (ORCID: https://orcid.org/0000-0003-4415-9657)
- Erika Yamashita (ORCID: https://orcid.org/0000-0002-3973-9529)
- Tetsuya Tanimoto (ORCID: https://orcid.org/0000-0002-9818-8587)
- Yudai Kaneda (ORCID: https://orcid.org/0000-0001-8302-9439)
- Kenji Gonda
- Hiroaki Saito (ORCID: https://orcid.org/0000-0002-0824-454X)
- Masahiro Wada (ORCID: https://orcid.org/0000-0002-2864-8410)
Institutions
- Hokkaido University (JP)
- Jyoban Hospital of Tokiwa Foundation (JP)
- Central Hokkaido Animal Health Center (JP)
- Medical Governance Research Institute (JP)
- Soma Central Hospital (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1371/journal.pone.0310880
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42